Germany-based Sandoz Inc has shipped pantoprazole sodium for injection, 40mg to Civica Rx, a US-based non-profit generic drug manufacturer, to supply the hospitals it serves, it was reported on Monday.
This move is part of a multiyear collaboration to help decrease supply shortages, with various other medicines that are on the way before the end of the year.
The product is the first Sandoz medicine to ship to Civica since entering into the contract in July. It is a proton pump inhibitor indicated in adults for the short-term treatment (seven to 10 days) of gastroesophageal reflux disease, associated with a history of erosive esophagitis. Sandoz previously stated that it will provide six injectable medicines under the Civica private label to its 1,200 US hospitals. The contract is being expanded to include an additional medicine to regulate blood pressure, which is frequently utilised to treat COVID-19 patients in hospitals.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US